Marina Atzenhoffer
Overview
Explore the profile of Marina Atzenhoffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crommelynck S, Grandvuillemin A, Ferard C, Mounier C, Gault N, Pierron E, et al.
Therapie
. 2024 Dec;
PMID: 39638686
In March 2020, World Health Organization recognized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emergence as a public health emergency of international concern. One of the major preventative measures developed...
2.
Thibault T, Ben Ghezala I, Freppel R, Rajillah A, Boulay C, Brunel P, et al.
Ophthalmology
. 2023 Oct;
131(2):249-251.
PMID: 37820932
No abstract available.
3.
Jonville-Bera A, Gautier S, Micallef J, Massy N, Atzenhoffer M, Grandvuillemin A, et al.
Therapie
. 2023 Apr;
78(5):467-475.
PMID: 37012154
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic virus was a "health crisis" and a significant burden also for the French pharmacovigilance system. It took its toll in 2...
4.
Bihan K, Lipszyc L, Lemaitre F, Dautriche A, Fedrizzi S, Atzenhoffer M, et al.
Therapie
. 2023 Apr;
78(5):531-547.
PMID: 37012153
Introduction: Nirmatrelvir/ritonavir (Paxlovid®) is currently one of the few therapeutic options for coronavirus disease 2019 (COVID-19) curative treatment in non-oxygen-requiring adult patients at-high risk of progressing to severe disease. This...
5.
Jonville-Bera A, Gautier S, Micallef J, Massy N, Atzenhoffer M, Drici M, et al.
Therapie
. 2023 Mar;
78(5):477-488.
PMID: 36890032
The pandemic subsequent to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus resulted, for the French institutional pharmacovigilance, in a "health crisis" in 2 phases: the coronavirus disease 2019 ...
6.
Massy N, Atzenhoffer M, Boulay C, Pecquet P, Ledys F, Cracowski J, et al.
Therapie
. 2023 Feb;
78(5):489-498.
PMID: 36759287
As part of the COVID-19 vaccination campaign, the National Agency for the Safety of Medicines and Health Products and all 31 regional pharmacovigilance centers were mobilized in an exceptional reinforced...
7.
Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, et al.
Eur J Cancer
. 2022 Dec;
179:28-47.
PMID: 36473326
Background: Generalised oedema was occasionally reported associated with immune checkpoint inhibitors (ICPIs). The purpose of this study is to investigate immune-related generalised oedema (ir-GE) drug related to ICPI, through frequency,...
8.
Martin M, Nguyen H, Beuvon C, Bene J, Palassin P, Atzenhoffer M, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291814
Immune checkpoint inhibitor (ICI)-related cytopenias have been poorly described. This study aimed to further characterize ICI-related cytopenias, using the French pharmacovigilance database. All grade ≥ 2 hematological adverse drug reactions...
9.
Bertin B, Grenet G, Pizzoglio-Billaudaz V, Lepelley M, Atzenhoffer M, Vial T
Therapie
. 2022 Aug;
78(3):279-292.
PMID: 36038397
The association between vaccines and peripheral facial palsy (PFP), an issue that has been the subject of debate for many years, has been raised again following results of clinical trials...
10.
Pluye M, Gouraud A, Herve M, Le H, Dagonneau T, Dalle S, et al.
Therapie
. 2022 Jul;
78(3):303-311.
PMID: 35906145
Introduction: Data on adverse drug reactions (ADRs) of immune checkpoint inhibitors (ICIs) used in oncology are mainly derived from clinical trials or cancer-specific reviews. We aim to analyze ADRs that...